

Anti-LAG3 [Polyclonal]

Catalog No.	Description		
AR917-5RE	6 ml of Ready-to-Use Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system		
AR917-10RE	10 ml of Ready-to-Use Antibody in a barcode labeled vial for use with BioGenex Super Sensitive TM Detection Systems and i6000 TM Automated Staining Systems		
PU917-UPE	1 ml of Concentrated Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system		
PU917-5UPE	0.5 ml of Concentrated Antibody for use with BioGenex Super Sensitive TM Detection		
	Systems OR equivalent detection system		
AW917-YCDE	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx [®] Elite/Ultra Staining System, 160 tests		
AW917-50DE	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx [®] Elite/Ultra Staining System, 50 tests		

Clone	Species	Ig Class
Polyclonal	Rabbit	IgG

Intended Use

For In Vitro Diagnostic Use. This antibody is designed for the specific localization of LAG3 in formalin-fixed, paraffinembedded (FFPE) tissue sections. Evaluation must be performed by a qualified pathologist.

Summary and Explanation

LAG-3 (Lymphocyte Activation Gene 3) or CD223 belongs to the Ig superfamily and has high homology to CD4. LAG-3 is an inhibitory T-cell surface molecule that has been found to directly modulate T-cell homeostasis (1). LAG3 is expressed on populations of activated T cells, such as Tregs and natural killer (NK) cells, and some monocyte-derived cell populations (2, 3). LAG3 negatively regulates cellular proliferation, activation, and homeostasis of T cells, and has been reported to play a role in Treg suppressive function (4). LAG3 is often co-expressed with PD-1 on the surface of tumor infiltrating lymphocytes, where the two proteins act independently to synergistically promote tumoral immune escape.

Storage and Handling

Store at 2-8°C. Fresh dilutions, if required, should be prepared prior to use and are stable and steady for up to one day at room temperature (20-26°C). Diluted antibody preparations can be refrigerated or frozen for extended shelf life.

EMERGO Europe, Prinsessegracht 20, 2514AP The Hague, The Netherlands

Principles of the Procedure

Antigen detection by immunohistochemistry (IHC) is a two-step process wherein the primary antibody binds to the antigen of interest and that binding is detected by a chromogen. The <u>primary antibody</u> may be used in IHC using manual techniques or BioGenex Automated Staining System. Positive and negative controls should always be run simultaneously with all patient specimens.

Reagents Provided

Rabbit Polyclonal Antibody LAG3 is affinity purified and diluted in PBS, pH 7.2, containing 1% BSA and 0.09% sodium azide.

Dilution of Primary Antibody

BioGenex Ready-to-Use antibodies have been optimized for use with the recommended BioGenex Detection System and should not require further dilution.

BioGenex concentrated antibodies must be diluted in accordance with the recommended protocol when used with the recommended BioGenex Detection System.

Recommended Protocol

Refer to the following table for conditions specifically recommended for this antibody. Refer to the BioGenex website for guidance on specific staining protocols or other requirements.

Parameter	BioGenex	
	Recommendations	
	Tonsil as available with	
Control Tissue	BioGenex FB-917PE* & FG-	
Control Tissue	917PE*	
Recommended Dilution for	1:50-100 in HK941	
Concentrated Antibody		
Recommended Pretreatment	EZ-AR2 (HK522-XAK)	
(Manual/i6000)**		
Recommended	EZ-AR2 Elegance (HX032-	
Pretreatment (Xmatrx)	YCD)	
Tretreatment (Amatra)		
Antibody Incubation	30 -60 min at RT	
(Manual/i6000)		
Antibody Incubation	30 -60 min at RT	
(Xmatrx)		
	Use BioGenex Two-Step OR	
Detection System for	One-Step Super Sensitive TM	
Manual, Xmatrx & i6000	Polymer-HRP IHC Detection	
systems***	System/DAB; see p. 2 for more	
	information	

^{*}FB: positive control micro chamberslides, FG: positive control microscopic slides. Xmatrx requires micro chamberslides.

^{**}Pretreatment times will vary based on individual microwave power. ***For automation systems (Xmatrx-Elite, Xmatrx-Ultra & i6000 Diagnostics), refer to the factory protocols provided with the instrument.

Category	Antibodies	Revision No.	G
Document No.	932-917P-EN	Release Date	11-Jan-2022



ϵ	Emergo Europe, Prinsessegracht 20, 2514AP The Hague, The Netherlan
EC RE	2

Detection	Two-Step	One-Step	Link and
System	HRP Kit	HRP Kit	Label Kit
Manual	QD440-XAKE (1000 Test) QD430-XAKE (1000 Test)	QD630-XAKE (1000 Test)	QP300-XAKE (1000 Test)
Manuai	QD420-YIKE (500 Test) QD400-60KE (60 Test)	QD620-XAKE (500 Test)	QP900-9LE (500 Test)
Xmatrx -	QD550-YCDE	QD610-YADE	N/A
Automation	(200 Test)	(200 Test)	
i6000 -	QD410-YAXE	QD610-YAXE	N/A
Automation	(200 Test)	(200 Test)	
For more information, visit <u>www.biogenex.com</u> .			

Precautions

This product contains sodium azide at concentrations of less than 0.1%. Sodium azide is not classified as a hazardous chemical at the product concentrations, but proper handling protocols should be observed. For more information, a Safety Data Sheet (SDS) for sodium azide is available upon request. Dispose of unused reagents according to Local, State and Federal Regulations. Wear suitable Personal Protective Equipment, do not pipette reagents by mouth, and avoid contact of reagents and specimens with skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with copious amounts of water.

Quality Control

Refer to BioGenex detection system documents for guidance on general quality control procedures.

Troubleshooting

Refer to the troubleshooting section in the documentation for BioGenex Detection Systems (or equivalent detection systems) for remedial actions on detection system related issues, or contact BioGenex Technical Support Department at 1-800-421-4149 or support@biogenex.com or your local distributor to report unusual staining.

Expected Results

This antibody stains nucleus/cytoplasm in positive cells in formalin-fixed, paraffin embedded tissue sections. An example image of a tissue section stained with this antibody can be found on the product page on the BioGenex website. Interpretation of the staining result is solely the responsibility of the user. Experimental results should be confirmed by a medicallyestablished diagnostic product or procedure.

Limitations of the Procedure

Improper tissue handling and processing prior to immunostaining can lead to inconsistent results. Variations in embedding and fixation or the nature of the tissue may lead to variations in results. Endogenous peroxidase activity or pseudo peroxidase activity in erythrocytes and tissue biotin may result in non-specific staining based on the detection system employed. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive with horseradish peroxidase systems. Improper counterstaining and mounting may compromise the interpretation of results.

Bibliography

- 1. Workman CJ, Vignali DA. Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J Immunol. 174 (2) 688-95 (2005).
- 2. Macon-Lemaitre L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 coreceptor (CD223) on human T cells. Immunology. 115 (2) 170-8 (2005).
- 3. Poirier N, Antibodymediated depletion of lymphocyte-activation gene-3 (LAG-3(+))-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates. Clin Exp Immunol. 164 (2) 265-74 (2011).
- 4. Huang CT, et al. "Role of LAG-3 in regulatory T cells". Immunity. 21 (4) 503-13 (2004).
- 5. Woo SR, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Research. 72 917-27, (2012).

2°C 8°C	Temperature Limitation	IVD	In Vitro Diagnostic Medical Device
\boxtimes	Use By Date	LOT	Batch Code
NON STERILE	Non-Sterile	[]i	Consult Instructions for Use
EC REP	Representative in the European Community	***	Manufacturer

© 2020, BioGenex Laboratories. All rights reserved.

Category	Antibodies	Revision No.	G
Document No.	932-917P-EN	Release Date	11-Jan-2022